(Q33378032)

English

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

0 references

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials (English)

1 reference

Europe PubMed Central

26 July 2017

gram-positive bacteria

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Matthew E. Falagas

1

object named as

Matthew E Falagas

1 reference

Europe PubMed Central

26 July 2017

Konstantinos Z Vardakas

3

object named as

Konstantinos Z Vardakas

1 reference

Europe PubMed Central

26 July 2017

author name string

Ilias I Siempos

2

1 reference

Europe PubMed Central

26 July 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

26 July 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

26 July 2017

8

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

53-66

1 reference

Europe PubMed Central

26 July 2017

Epidemiology of methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus as a community organism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Community-acquired methicillin-resistant Staphylococcus aureus infections in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in community-acquired methicillin-resistant Staphylococcus aureus in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for ICU-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of nosocomial pneumonia. New perspectives on an old disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial infections in combined medical-surgical intensive care units in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital-acquired infections: diseases with increasingly limited therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increasing threat of Gram-positive bacterial infections in the intensive care unit setting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in antimicrobial-drug resistance in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The economic impact of Staphylococcus aureus infection in New York City hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Health and economic impacts of antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Staphylococcal skin infections in children: rational drug therapy recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A practical guide to the treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid absolute bioavailability and the effect of food on oral bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid eradicates MRSA better than vancomycin from surgical-site infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid for the treatment of complicated skin and skin structure infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Penetration of vancomycin into human lung tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrapulmonary pharmacokinetics of linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic effects of linezolid in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970312-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(07)70312-2

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33378032&oldid=1635667811"